Abstract
The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51%) expressing only myeloid antigens (My/AML) and 54/110 (49%) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70%), was rarely expressed in M0 + M1 cases (9%). On the contrary, CD34, expressed in 77% of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6% and 7%, respectively). CD2 and CD7 antigens were found in 34% and 42% of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31% and 18% of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65% versus 82%) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.
| Original language | English |
|---|---|
| Pages (from-to) | 428-434 |
| Number of pages | 7 |
| Journal | Stem Cells |
| Volume | 13 |
| Issue number | 4 |
| Publication status | Published - 1995 |
Fingerprint
Keywords
- AML surface antigens
- CD34
- CD7
- CR
- mAbs
ASJC Scopus subject areas
- Cell Biology
Cite this
The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance. / Lauria, F.; Raspadori, D.; Ventura, M. A.; Rondelli, D.; Testoni, N.; Tosi, P.; Michieli, M.; Damiani, D.; Motta, M. R.; Tura, S.
In: Stem Cells, Vol. 13, No. 4, 1995, p. 428-434.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The presence of lymphoid-associated antigens in adult acute myeloid leukemia is devoid of prognostic relevance
AU - Lauria, F.
AU - Raspadori, D.
AU - Ventura, M. A.
AU - Rondelli, D.
AU - Testoni, N.
AU - Tosi, P.
AU - Michieli, M.
AU - Damiani, D.
AU - Motta, M. R.
AU - Tura, S.
PY - 1995
Y1 - 1995
N2 - The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51%) expressing only myeloid antigens (My/AML) and 54/110 (49%) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70%), was rarely expressed in M0 + M1 cases (9%). On the contrary, CD34, expressed in 77% of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6% and 7%, respectively). CD2 and CD7 antigens were found in 34% and 42% of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31% and 18% of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65% versus 82%) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.
AB - The immunophenotype of 110 adult patients with diagnosis of acute myeloblastic leukemia (AML) was analyzed using a wide panel of monoclonal antibodies (mAbs). Leukemic blasts were tested by applying direct immunofluorescence analysis and dual-fluorescence staining, and two groups of patients were identified: 56/110 (51%) expressing only myeloid antigens (My/AML) and 54/110 (49%) expressing both myeloid and lymphoid antigens (Ly/AML), CD13 and CD33 were expressed in almost all FAB subtypes, whereas CD14, frequently expressed in M4 and M5 subtypes (70%), was rarely expressed in M0 + M1 cases (9%). On the contrary, CD34, expressed in 77% of M0 + M1 cases, was practically absent in M3 and M5 subtypes (6% and 7%, respectively). CD2 and CD7 antigens were found in 34% and 42% of patients respectively, whereas B cell-associated antigens, such as CD10 and CD19, were found in 31% and 18% of patients. Cytogenetic abnormalities characteristically present in AML patients were also analyzed and, except for t(8;21) which was found in both groups of patients, the other abnormalities were frequently found in cases coexpressing lymphoid-associated antigens. Finally, the complete remission (CR) rate, survival and event-free survival were analyzed according to the presence of lymphoid markers and also of some specific antigens such as CD7 and CD34. The only prognostic difference was represented by CD34+ patients who showed a reduction in the CR rate compared with CD34- patients (65% versus 82%) (p = 0.05) which became more evident when the mean intensity of fluorescence was considered. In conclusion, mAbs conjugated with fluorochromes and analyzed by more sophisticated cytometers allow the identification of a higher number of AML cases bearing lymphoid- associated antigens, but this phenotypic coexpression is not associated with biologically distinct forms of leukemia.
KW - AML surface antigens
KW - CD34
KW - CD7
KW - CR
KW - mAbs
UR - http://www.scopus.com/inward/record.url?scp=0029026795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029026795&partnerID=8YFLogxK
M3 - Article
C2 - 7549902
AN - SCOPUS:0029026795
VL - 13
SP - 428
EP - 434
JO - Stem Cells
JF - Stem Cells
SN - 1066-5099
IS - 4
ER -